Literature DB >> 31548340

Modulators of CXCR4 and CXCR7/ACKR3 Function.

Ilze Adlere1, Birgit Caspar1, Marta Arimont1, Sebastian Dekkers1, Kirsten Visser1, Jeffrey Stuijt1, Chris de Graaf1, Michael Stocks1, Barrie Kellam1, Stephen Briddon1, Maikel Wijtmans1, Iwan de Esch1, Stephen Hill1, Rob Leurs2.   

Abstract

The two G protein-coupled receptors (GPCRs) C-X-C chemokine receptor type 4 (CXCR4) and atypical chemokine receptor 3 (ACKR3) are part of the class A chemokine GPCR family and represent important drug targets for human immunodeficiency virus (HIV) infection, cancer, and inflammation diseases. CXCR4 is one of only three chemokine receptors with a US Food and Drug Administration approved therapeutic agent, the small-molecule modulator AMD3100. In this review, known modulators of the two receptors are discussed in detail. Initially, the structural relationship between receptors and ligands is reviewed on the basis of common structural motifs and available crystal structures. To date, no atypical chemokine receptor has been crystallized, which makes ligand design and predictions for these receptors more difficult. Next, the selectivity, receptor activation, and the resulting ligand-induced signaling output of chemokines and other peptide ligands are reviewed. Binding of pepducins, a class of lipid-peptides whose basis is the internal loop of a GPCR, to CXCR4 is also discussed. Finally, small-molecule modulators of CXCR4 and ACKR3 are reviewed. These modulators have led to the development of radio- and fluorescently labeled tool compounds, enabling the visualization of ligand binding and receptor characterization both in vitro and in vivo. SIGNIFICANCE STATEMENT: To investigate the pharmacological modulation of CXCR4 and ACKR3, significant effort has been focused on the discovery and development of a range of ligands, including small-molecule modulators, pepducins, and synthetic peptides. Imaging tools, such as fluorescent probes, also play a pivotal role in the field of drug discovery. This review aims to provide an overview of the aforementioned modulators that facilitate the study of CXCR4 and ACKR3 receptors.
Copyright © 2019 by The Author(s).

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31548340     DOI: 10.1124/mol.119.117663

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

1.  Discovery of Diphenylacetamides as CXCR7 Inhibitors with Novel β-Arrestin Antagonist Activity.

Authors:  Elnaz Menhaji-Klotz; Jessica Ward; Janice A Brown; Paula M Loria; Carina Tan; Kevin D Hesp; Keith A Riccardi; John Litchfield; Markus Boehm
Journal:  ACS Med Chem Lett       Date:  2020-05-14       Impact factor: 4.345

Review 2.  Heterotrimeric Gq proteins as therapeutic targets?

Authors:  Evi Kostenis; Eva Marie Pfeil; Suvi Annala
Journal:  J Biol Chem       Date:  2020-03-02       Impact factor: 5.157

Review 3.  Germinal Center-Related G Protein-Coupled Receptors in Antibody-Mediated Autoimmune Skin Diseases: from Basic Research to Clinical Trials.

Authors:  Pengpeng Cao; Ming Yang; Christopher Chang; Haijing Wu; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2022-06-08       Impact factor: 8.667

Review 4.  CXCR4 as a novel target in immunology: moving away from typical antagonists.

Authors:  Birgit Caspar; Pietro Cocchiara; Armelle Melet; Kristof Van Emelen; Annegret Van der Aa; Graeme Milligan; Jean-Philippe Herbeuval
Journal:  Future Drug Discov       Date:  2022-07-19

Review 5.  Harnessing cytokines and chemokines for cancer therapy.

Authors:  David J Propper; Frances R Balkwill
Journal:  Nat Rev Clin Oncol       Date:  2022-01-07       Impact factor: 65.011

Review 6.  CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment.

Authors:  Sara Santagata; Caterina Ieranò; Anna Maria Trotta; Anna Capiluongo; Federica Auletta; Giuseppe Guardascione; Stefania Scala
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

Review 7.  Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy.

Authors:  Shuyang Sun; Ziqiang Ding; Xiaomei Yang; Xinyue Zhao; Minlong Zhao; Li Gao; Qu Chen; Shenxia Xie; Aiqun Liu; Shihua Yin; Zhiping Xu; Xiaoling Lu
Journal:  Int J Nanomedicine       Date:  2021-03-22

8.  Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists.

Authors:  Ali Işbilir; Jan Möller; Marta Arimont; Vladimir Bobkov; Cristina Perpiñá-Viciano; Carsten Hoffmann; Asuka Inoue; Raimond Heukers; Chris de Graaf; Martine J Smit; Paolo Annibale; Martin J Lohse
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-04       Impact factor: 11.205

9.  Automated Synthesis of Fluorine-18 Labeled CXCR4 Ligand via the Conjugation with Nicotinic Acid N-Hydroxysuccinimide Ester (6-[18F]SFPy).

Authors:  Falguni Basuli; Xiang Zhang; Tim E Phelps; Elaine M Jagoda; Peter L Choyke; Rolf E Swenson
Journal:  Molecules       Date:  2020-08-27       Impact factor: 4.411

Review 10.  Atypical Roles of the Chemokine Receptor ACKR3/CXCR7 in Platelet Pathophysiology.

Authors:  Madhumita Chatterjee
Journal:  Cells       Date:  2022-01-09       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.